Immediate Impact

3 by Nobel laureates 10 from Science/Nature 68 standout
Sub-graph 1 of 23

Citing Papers

The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial
2025 Standout
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
2023 StandoutNobel
1 intermediate paper

Works of RS Finn being referenced

LBA36 Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma
2022
A phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results
2019

Author Peers

Author Last Decade Papers Cites
RS Finn 573 365 224 40 778
J.M.G.H. van Riel 708 408 375 25 968
Jia Luo 502 443 280 63 966
G. R. Blumenschein 606 509 175 54 986
J. Jac 220 422 203 25 751
Muaiad Kittaneh 440 306 143 40 722
Anne‐Claire Voegeli 346 448 151 25 742
Chin‐Tung Chen 569 257 149 22 974
Álvaro Taus 528 402 219 61 845
Erwan Pencreach 342 189 245 35 770
J.P. Delord 696 274 161 48 960

All Works

Loading papers...

Rankless by CCL
2026